Clinical Trial Update: Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating venetoclax in combination with five days of azacitidine in untreated acute myeloid leukemia patients who are not eligible fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Leipzig | Conditions: Acute Myeloid Leukemia (AML) | Phase 2 | Status: RECRUITING